|
| Status |
Public on Nov 02, 2012 |
| Title |
C23_3 |
| Sample type |
RNA |
| |
|
| Source name |
C23
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: HeLa
genotype/variation: transfected with nucleolin siRNA
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Trizol according to manufacture's instructions
|
| Label |
n/a
|
| Label protocol |
RNA was not labeled; instead, RNA (33 ng/ul) was pre-processed following the NanoString manufacturer's protocol by the Ohio State Microarray Core Facility
|
| |
|
| Hybridization protocol |
Hybrdization reactions were performed according to the manufacturer's instructions (NanoString.com) with 5 Āµl of the 5-fold diluted sample preparation reaction. All hybridization reactions were incubated at 65Ā°C for a minimum of 18 h.
|
| Scan protocol |
Hybridized probes were purified and counted on the nCounter Prep Station and Digital Analyzer (NanoString) following the manufacturerās instructions. For each assay, a high-density scan (600 fields of view) was performed
|
| Description |
HeLa transfected with nucleolin siRNA
|
| Data processing |
The data were normalized for lane-to-lane variation with a dilution series of six spike-in positive controls using code count normalization according to manufacturer's protocol (Nanostring). We then applied Variance Stabilization algorithm (vsn). In the normalized table we removed the control probes (Positive and Negative Controls, Housekeeping genes and viral microRNAs).
|
| |
|
| Submission date |
Nov 01, 2012 |
| Last update date |
Nov 02, 2012 |
| Contact name |
Luciano Cascione |
| E-mail(s) |
luciano.cascione@ior.usi.ch
|
| Organization name |
IOR
|
| Department |
Lymphoma & Genomics Research Program
|
| Street address |
Via Chiesa 5
|
| City |
Bellinzona |
| State/province |
Ticino |
| ZIP/Postal code |
6500 |
| Country |
Switzerland |
| |
|
| Platform ID |
GPL16231 |
| Series (2) |
| GSE41971 |
In vivo NCL-targeting affects breast cancer aggressiveness through miRNA regulation [NanoString] |
| GSE41973 |
In vivo NCL-targeting affects breast cancer aggressiveness through miRNA regulation |
|
